Psoriasis: modest 1-year efficacy with apremilast, but AEs are common

  • Del Alcázar E & al.
  • J Eur Acad Dermatol Venereol
  • 9 Apr 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In a retrospective study, almost half of patients receiving apremilast achieved ≥75% improvement in Psoriasis Area and Severity Index (PASI 75) at 12 months, although gastrointestinal problems were common.

Why this matters

  • Little is known about the real-world effectiveness and safety of apremilast.

Key results

  • At 1 year, 49.7% of patients achieved PASI 75 and 26.5% achieved PASI 90.
  • Mean physician global assessment score for palmoplantar psoriasis decreased from 4.2 at baseline to 1.3 at week 52.
  • 1-year drug survival was 54.9%.
  • The most common reasons for treatment discontinuation were loss of efficacy (23.9%) and adverse events (AEs; 15.9%).
  • 47% of patients experienced ≥1 AE; the most common were gastrointestinal problems and asthenia.

Study design

  • 292 patients with plaque psoriasis and 85 patients with palmoplantar psoriasis who were treated with apremilast were included.
  • Funding: None.

Limitations

  • Retrospective.